Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
The phase 3 randomized controlled trial of extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (PM) (MARS2) reported “extended pleurectomy decortication was…
In this issue of Blood, Ito et al1 present a compelling cost-effectiveness analysis of iptacopan for patients with paroxysmal nocturnal hemoglobinuria (PNH
Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, comments on a retrospective analysis assessing the efficacy of combining venetoclax with intensive purine analog-based…
Olverembatinib demonstrated preliminary efficacy and was well tolerated in patients with heavily pretreated chronic-phase myeloid leukemia.
Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.
The phase 3 MECCA trial represents the largest data set investigating the efficacy of metronomic chemo-endocrine combination therapy in metastatic breast cancer, according to researchers.
The FDA has issued a draft guidance offering recommendations regarding tissue biopsies in clinical trials for pediatric and adult patients.
When it comes to cancer prevention and early detection, knowledge can be power.
Josep Maria Ribera, MD, PhD, discusses the current standard treatment protocols for Philadelphia chromosome-positive acute lymphoblastic leukemia and the rationale behind them.
An acalabrutinib triplet elicited a high response rate in patients with de novo mantle cell lymphoma.
